Natco Pharma share price
NSE: NATCOPHARMBSE: 524816Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹785.15.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹15,534 Cr380th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 14 Aug 2026
- 13.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.57%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- 13.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- 8.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.08
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 5,69,53550.8% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 14 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹735 Crdown 0.53%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹207 Crdown 23.23%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 28.1%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 12 Nov | Dec 2024Filed 12 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 12 Aug | Sep 2025Filed 14 Nov | Dec 2025Filed 12 Feb | Mar 2026Filed 29 May | Jun 2026Filed 14 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,371 | 475 | 1,221 | 1,329 | 1,363 | 647 | 739 | 735 |
| Net profit | 677 | 132 | 406 | 480 | 518 | 151 | 269 | 207 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 49.3% | 27.9% | 33.3% | 36.1% | 38.0% | 23.4% | 36.4% | 28.1% |
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- PharmaceuticalsPharmaceuticals, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹3,940 Crdown 9.81%96.6%
- Agro chemicalsAgro chemicals, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹138 Crup 128.05%3.4%
Valuation
Today, against the company's own history. Not shown, P/B: the share count changed after the latest balance sheet (a rights issue, a buyback, an allotment or a listing), which does not yet hold the money it brought or returned. Not shown, EV/EBITDA: the share count changed after the latest balance sheet (a rights issue, a buyback, an allotment or a listing), which does not yet hold the money it brought or returned.PE ratio and valuation history
At or below today's level on 24% of 2,480 trading days over the last 10 years.
At or below today's level on 22% of 2,480 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +22.5% | −24.8% | +62.1% | 0.5% |
| 3 years | +20.8% | +26.4% | −5.1% | 0.8% |
| 5 years | +4.1% | +26.8% | −18.5% | 0.8% |
Mutual funds holding it
83 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 63 of the 66 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 26
- CutCut. Funds that held fewer shares than at the end of the month before.
- 40
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 13
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 2
| Fund | |||
|---|---|---|---|
 Tata Small Cap FundTata Mutual Fund | 8,28,616 | 0.52% | ₹68.6 Cr |
| Tata Value FundTata Mutual Fund | 7,00,001 | 0.70% | ₹57.9 Cr |
 Sundaram Small Cap FundSundaram Mutual Fund | 5,51,707 | 1.11% | ₹45.7 Cr |
| Tata India Pharma & Healthcare FundTata Mutual Fund | 2,75,137 | 1.51% | ₹22.8 Cr |
 Bandhan Multi Cap FundBandhan Mutual Fund | 2,75,000 | 0.77% | ₹22.8 Cr |
 quant Healthcare Fundquant Mutual Fund | 1,54,500 | 3.01% | ₹12.8 Cr |
 Nippon India Nifty Smallcap 250 Index FundNippon India Mutual Fund | 1,38,942 | 0.33% | ₹11.5 Cr |
 Aditya Birla Sun Life Pharma and Healthcare FundAditya Birla Sun Life Mutual Fund | 1,20,000 | 0.92% | ₹9.93 Cr |
 HDFC Nifty Smallcap 250 ETFHDFC Mutual Fund | 1,09,023 | 0.33% | ₹9.02 Cr |
 Axis Nifty Smallcap 50 Index FundAxis Mutual Fund | 82,108 | 0.87% | ₹6.79 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Natco Pharma in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Cohance LifesciencesCOHANCE | 17,211 | 162.0 | 4.4 | 54.8 | +41.2% | −58.5% | 3.8% | 3.0% | 0.00% |
 Shilpa MedicareSHILPAMED | 16,904 | 56.9 | 6.5 | 36.6 | +27.9% | +167.6% | 12.0% | 10.9% | 0.07% |
 Caplin Point LaboratoriesCAPLIPOINT | 16,890 | 25.4 | 4.7 | 20.4 | +15.0% | +17.7% | 20.7% | 19.8% | 0.36% |
 PfizerPFIZER | 16,525 | 22.5 | 3.9 | 14.2 | +10.7% | −9.1% | 17.5% | 21.0% | 2.08% |
 Alivus Life SciencesALIVUS | 15,354 | 25.5 | 4.6 | 18.3 | +7.9% | +21.7% | 19.6% | 22.7% | 0.40% |
 Onesource Specialty PharmaONESOURCE | 15,299 | – | 2.6 | 48.6 | +27.2% | – | −0.8% | 0.8% | 0.00% |
 Eris LifesciencesERIS | 15,199 | 23.6 | 3.9 | 15.3 | +9.7% | +66.4% | 19.1% | 13.8% | 0.66% |
 AstraZeneca Pharma IndiaASTRAZEN | 14,971 | 88.3 | 17.2 | 63.2 | +31.1% | −7.5% | 20.6% | 24.4% | 0.60% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 20 Aug 2026 | Interim | ₹1.50 |
| 18 Feb 2026 | Interim | ₹1.50 |
| 20 Nov 2025 | Interim | ₹1.50 |
| 19 Aug 2025 | Interim | ₹2.00 |
| 18 Feb 2025 | Interim | ₹1.50 |
| 27 Nov 2024 | Interim | ₹1.50 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
28 Sep · Committee Meeting Updates
Natco Pharma share price by year
Each calendar year to 2025.Natco Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 903.05 | −34.9% | 1,397.30 | 746.50 |
| 2024 | 1,387.30 | +71.0% | 1,592.85 | 818.30 |
| 2023 | 811.35 | +44.5% | 914.25 | 523.90 |
| 2022 | 561.65 | −37.9% | 927.75 | 549.35 |
| 2021 | 904.65 | −6.0% | 1,162.05 | 790.40 |
| 2020 | 961.95 | +62.1% | 971.40 | 465.75 |
| 2019 | 593.45 | −12.7% | 703.40 | 502.65 |
| 2018 | 680.05 | −29.3% | 1,035.70 | 655.20 |
| 2017 | 961.70 | +65.9% | 1,077.45 | 583.30 |
| 2016 | 579.65 | +0.1% | 688.90 | 393.10 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 785.00 | 797.45 | 778.00 | 791.85 | 785.85 | 5,69,535 | 50.8% |
| 22 Oct 2026 | 780.00 | 789.00 | 773.60 | 785.15 | 783.49 | 6,99,649 | 63.9% |
| 21 Oct 2026 | 799.00 | 800.65 | 780.00 | 784.45 | 784.68 | 4,80,152 | 51.2% |
| 19 Oct 2026 | 785.05 | 809.80 | 779.50 | 800.85 | 799.60 | 7,68,065 | 26.9% |
| 16 Oct 2026 | 786.95 | 788.50 | 780.95 | 785.05 | 785.74 | 4,97,871 | 73.4% |
| 15 Oct 2026 | 784.00 | 787.60 | 779.00 | 784.95 | 784.05 | 2,97,976 | 65.1% |
| 14 Oct 2026 | 789.15 | 794.00 | 781.00 | 782.65 | 786.25 | 4,65,448 | 58.2% |
| 13 Oct 2026 | 800.55 | 802.65 | 787.20 | 789.15 | 792.06 | 2,77,749 | 58.8% |
| 12 Oct 2026 | 789.40 | 804.75 | 789.40 | 800.55 | 799.42 | 5,01,242 | 65.8% |
| 9 Oct 2026 | 795.40 | 801.70 | 787.45 | 789.40 | 793.50 | 2,33,109 | 48.7% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 1 Oct 2026 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
| 26 Nov 2015 | Split | 0.2000 | Each share became 5. |
About Natco Pharma
NATCO Pharma is a research-focused pharmaceutical company. Its business covers the development, manufacturing and marketing of finished dosage formulations, active pharmaceutical ingredients and agrochemicals. Its stated mission is making specialty medicines accessible to all.
Export formulations are its largest segment. The domestic formulations business is led by oncology, cardiology, diabetology and specialty divisions. The crop health sciences division, which sells agrochemicals, was started in 2019. The board has approved a demerger of this division, and the demerger is awaiting regulatory approval.
NATCO has a presence in more than 50 countries through 13 subsidiaries, step-down subsidiaries and an associate. It has set up its own front-ends in the USA, Canada, Brazil, the Philippines, Singapore, Australia and Indonesia. It has a team of more than 5,200 people worldwide.
In November 2025, its South African subsidiary completed the acquisition of a 34.88% stake in Adcock Ingram Holdings, the second-largest pharmaceutical company in South Africa by private market share. Adcock Ingram has a heritage dating back to 1890 and operates in prescription, over-the-counter, hospital and consumer healthcare segments. The purchase formed part of a scheme of arrangement through which Adcock Ingram was delisted from the Johannesburg Stock Exchange. A further stake bought in July 2026 took NATCO's ultimate holding to 49%.
NATCO was incorporated in 1981. It has grown from a single-unit operation with a small team into an international pharmaceutical company.
- Legal name
- Natco Pharma Limited
- NSE symbol
- NATCOPHARM
- BSE code
- 524816
- ISIN
- INE987B01026
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Apr 1995 on BSE, Dec 1995 on NSE
- Face value
- ₹2
- CIN
- L24230TG1981PLC003201
- Corporate identity number, the registrar of companies' code for it